Not yet recruitingPhase EARLY_1

Preoperative Semaglutide Prior to Radical Prostatectomy

A Prospective, Open-label, Exploratory Interventional Trial of Preoperative Semaglutide Prior to Radical Prostatectomy for Intermediate-risk Localized Prostate Cancer

Lead sponsor

Banner Health

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥35•Male

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07727473

Org study ID2241-2114

Timeline

Milestones

Study first posted2026-07-27actual

Last update posted2026-07-27actual

Study start2026-07estimated (month precision)

Primary completion2028-05estimated (month precision)

Study completion2029-05estimated (month precision)

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

SexMale

Healthy volunteersNot accepted

Inclusion criteria

•Male participants aged ≥18 years

•Biopsy-proven intermediate-risk localized prostate cancer per NCCN risk stratification criteria

•Planning to undergo radical prostatectomy, and surgical delay of 3-6 months is deemed appropriate by the investigator

•Body mass index (BMI) >35 kg/m²

•No prior exposure to androgen deprivation therapy or androgen receptor pathway inhibitors

Exclusion criteria

•Prostate cancer risk classification other than intermediate risk

•Hemoglobin A1c (HbA1c) >9%

•Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)

•Baseline gastroparesis, dysphagia, or other significant gastrointestinal disease limiting oral intake

•Current or recent (within 12 months) exposure to GLP-1 receptor agonist therapy

•Delay of radical prostatectomy by 3-6 months is not deemed advisable by the investigator

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.